Newcastle upon Tyne

Tonghai Financial Announces Appointment of Ambrose Lam as Co-Chairman of China Tonghai Capital (Holdings) Limited

Retrieved on: 
Tuesday, March 14, 2023
IBD, Institute of Chartered Accountants of Scotland, Certified Public Accountant, Newcastle University, Knowledge, Growth, Ambrose, Hong Kong Institute of Certified Public Accountants, Holding, Newcastle upon Tyne, University, Bank

HONG KONG, Mar 14, 2023 - (ACN Newswire) - China Tonghai International Financial Limited (Stock Code: 00952.HK) is pleased to announce that Mr. Ambrose Lam as the Co-Chairman of its wholly owned subsidiary China Tonghai Capital (Holdings) Limited (Tonghai Capital), with effect from January 15, 2023.

Key Points: 
  • HONG KONG, Mar 14, 2023 - (ACN Newswire) - China Tonghai International Financial Limited (Stock Code: 00952.HK) is pleased to announce that Mr. Ambrose Lam as the Co-Chairman of its wholly owned subsidiary China Tonghai Capital (Holdings) Limited (Tonghai Capital), with effect from January 15, 2023.
  • In the new role of Co-Chairman of China Tonghai Capital, Ambrose will support the Group in encompassing all of Tonghai Capital's businesses including IBD, Debt Capital Markets and Capital Market Solutions, providing our clients with a comprehensive service to facilitate their different financing demands.
  • Ambrose is joining Tonghai Financial with impressive track records, adding a wealth of experience at this important juncture.
  • He is expected to drive our corporate finance business into the future, with the clear objective to position Tonghai Financial for a successful future and realize its full potential.

Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer

Retrieved on: 
Tuesday, June 7, 2022
Oncology, Cairo University, Breast cancer, Institut Jules Bordet, Research, European Society for Medical Oncology, Society, Control, Doctor of Philosophy, Newcastle upon Tyne, ESMO, CEO, Medical degree, Cancer, ASCO, ADC, University, Therapy, American Society of Clinical Oncology, MD, Pharmaceutical industry, Emergence

Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (CMO), as of 6 June 2022.

Key Points: 
  • Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (CMO), as of 6 June 2022.
  • Dr. Hatem Azim joins Emergence Therapeutics from Pierre Fabre, a French multinational pharmaceutical company where he was Head of Oncology Early Clinical Development.
  • Jack Elands, CEO of Emergence Therapeutics, commented: I am delighted to welcome Hatem to Emergence as our Chief Medical Officer.
  • Hatem Azim commented: Emergence Therapeutics is on the frontier of developing novel, highly selective ADCs for the treatment of hard-to-treat cancers.

QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529

Retrieved on: 
Friday, November 26, 2021
Interview, Genome, Hospital, PCR, Financial adviser, Severe acute respiratory syndrome coronavirus 2, Computer simulation, COVID-19, Research, Marketing communications, RSV, UPON, Pharmacy, Animal, Medical device

QuantuMDx Group Limited (QuantuMDx), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC, as well as its future respiratory panel (SARS-CoV-2, Flu A, Flu B and RSV A/B), remain able to detect all known virus strains, including the latest variant, B.1.1.529.

Key Points: 
  • QuantuMDx Group Limited (QuantuMDx), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC, as well as its future respiratory panel (SARS-CoV-2, Flu A, Flu B and RSV A/B), remain able to detect all known virus strains, including the latest variant, B.1.1.529.
  • This is testament to the advanced assay design deployed by the QuantuMDx and further underlines the quality of the companys products.
  • QuantuMDx tackles real-world diagnostic problems by delivering molecular point of care solutions for anyone, anywhere.
  • Jonathan OHalloran, Chief Executive, QuantuMDx, is available for interview on the subject of the new Covid variant, B.1.1.529, and the importance of PCR testing.

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Retrieved on: 
Monday, November 8, 2021
Dai, Pharmacy, Strategic Cooperation Agreement, Strategic management, PCR, Technology, STI, Shanghai Stock Exchange, HPV, Research, STAR, Hospital, Company, Financial adviser, Solution, Swan House and Vita Spring Pavilion, Pharmaceutical industry, Renewable energy, Medical device

QuantuMDx Group Limited (QuantuMDx), today announces it has secured a 15 million equity investment from Vita Spring IVD Fund, L.P. (Vita Spring), a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.

Key Points: 
  • QuantuMDx Group Limited (QuantuMDx), today announces it has secured a 15 million equity investment from Vita Spring IVD Fund, L.P. (Vita Spring), a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.
  • Additionally, QuantuMDx and Sansure Biotech Inc. (Sansure) have entered discussions for a Cooperation Agreement.
  • Sansure is an in-vitro diagnostic solution provider founded in Changsha, Hunan province, China in 2008, with over 1,500 employees and a broad product portfolio.
  • Sansures founder and Chairman, Dr Li Zhong Dai, is a scientific advisor to Vita Spring.

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Retrieved on: 
Monday, November 8, 2021
Dai, Pharmacy, Strategic Cooperation Agreement, Strategic management, PCR, Technology, STI, Shanghai Stock Exchange, HPV, Research, STAR, Hospital, Company, Financial adviser, Solution, Swan House and Vita Spring Pavilion, Pharmaceutical industry, Renewable energy, Medical device

QuantuMDx Group Limited (QuantuMDx), today announces it has secured a 15 million equity investment from Vita Spring IVD Fund, L.P. (Vita Spring), a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.

Key Points: 
  • QuantuMDx Group Limited (QuantuMDx), today announces it has secured a 15 million equity investment from Vita Spring IVD Fund, L.P. (Vita Spring), a Hong Kong-based venture capital firm focused on early and growth stage medical device companies with disruptive technologies and global market potential.
  • Additionally, QuantuMDx and Sansure Biotech Inc. (Sansure) have entered discussions for a Cooperation Agreement.
  • Sansure is an in-vitro diagnostic solution provider founded in Changsha, Hunan province, China in 2008, with over 1,500 employees and a broad product portfolio.
  • Sansures founder and Chairman, Dr Li Zhong Dai, is a scientific advisor to Vita Spring.

QuantuMDx launches Q-POC™ - rapid PCR point of care diagnostic system

Retrieved on: 
Friday, July 9, 2021
Biotechnology, Branches of biology, Life sciences, Biology, Medical tests, Molecular biology, Laboratory techniques, Hoffmann-La Roche, Polymerase chain reaction, Molecular diagnostics

QuantuMDx Group Limited (QuantuMDx or the Company), a UK-based developer of transformational point-of-care diagnostics, today announces the launch of Q-POC - a rapid, PCR point of care diagnostic system.

Key Points: 
  • QuantuMDx Group Limited (QuantuMDx or the Company), a UK-based developer of transformational point-of-care diagnostics, today announces the launch of Q-POC - a rapid, PCR point of care diagnostic system.
  • Q-POC is a portable PCR system which compresses an entire molecular diagnostic laboratory into a simple to use, accessible and affordable single device offering rapid, molecular diagnostic testing at the point of care, with results in approximately 30 minutes.
  • Its a true point of care diagnostic system.
  • For more information about QuantuMDx and Q-POC, its rapid PCR point of care system, go to: www.quantumdx.com.

Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

Retrieved on: 
Saturday, February 13, 2021

QuantuMDx Group Limited, a UK-based diagnostics company which has developed a revolutionary 30 minute PCR diagnostics device, Q-POC, and accompanying SARS-CoV-2 test, today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle upon Tyne.

Key Points: 
  • QuantuMDx Group Limited, a UK-based diagnostics company which has developed a revolutionary 30 minute PCR diagnostics device, Q-POC, and accompanying SARS-CoV-2 test, today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle upon Tyne.
  • The Q-POCTM has been designed for rapid PCR testing in clinical settings to ensure the safety of our NHS frontline healthcare workers.
  • We were delighted to welcome the Prime Minister, the Rt Hon Boris Johnson MP, to QuantuMDx today and we are grateful for his and the governments support.
  • QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa keeping it at the forefront of molecular diagnostics.

QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012/01

Retrieved on: 
Tuesday, December 22, 2020
Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Bat virome, GISAID, Influenza A virus subtype H5N1, Severe acute respiratory syndrome coronavirus, Coronavirus disease, Severe acute respiratory syndrome

QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012/01

Key Points: 
  • QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012/01
    NEWCASTLE UPON TYNE, UK, 22 December 2020.
  • QuantuMDx Group Limited (QuantuMDx), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2.
  • The UK COVID Genomics Consortium and Public Health England have identified a new strain of SARS-CoV-2 which is characterised by multiple spike gene variants.
  • QuantuMDx continually monitors genomic sequences deposited to the NCBI and GISAID databases as part of post market surveillance.

QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette

Retrieved on: 
Thursday, December 17, 2020
Medicine, Life sciences, Medical tests, Health, Biotechnology, Medical terminology, Point-of-care testing, Polymerase chain reaction, Molecular diagnostics, POC, Point of care

QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over 11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC and disposable test cassette.

Key Points: 
  • QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over 11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC and disposable test cassette.
  • QuantuMDx accelerated development, scale-up and manufacture of Q-POC - its rapid point-of-care testing system - earlier this year in response to the COVID-19 pandemic.
  • Q-POC is a portable, PCR device offering rapid, sample-to-answer, molecular diagnostic testing at the point of care, with results in approximately 30 minutes.
  • The Q-POC system comprises a sample collection kit, single-use test cassette and analyser.

QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette

Retrieved on: 
Thursday, December 17, 2020
Medicine, Life sciences, Medical tests, Health, Biotechnology, Medical terminology, Point-of-care testing, Polymerase chain reaction, Molecular diagnostics, POC, Point of care

QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over 11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC and disposable test cassette.

Key Points: 
  • QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announced it is investing over 11 million to scale up production to mass manufacture its flagship diagnostic device, Q-POC and disposable test cassette.
  • QuantuMDx accelerated development, scale-up and manufacture of Q-POC - its rapid point-of-care testing system - earlier this year in response to the COVID-19 pandemic.
  • Q-POC is a portable, PCR device offering rapid, sample-to-answer, molecular diagnostic testing at the point of care, with results in approximately 30 minutes.
  • The Q-POC system comprises a sample collection kit, single-use test cassette and analyser.